Hogan Lovells advised Altavant Sciences in its acquisition of Onspira Therapeutics
New York, 8 January 2020 – International law firm Hogan Lovells advised clinical-stage biopharmaceutical company Altavant Sciences in its acquisition of Onspira Therapeutics, a private drug development company similarly focused on therapeutics for rare pulmonary diseases.
This acquisition expanded Altavant’s pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with US FDA orphan drug designation. OSP-101 is in development for the treatment of bronchiolitis obliterans syndrome (BOS), the leading cause of morbidity and mortality in post-lung transplant patients.
“Hogan Lovells offers an unparalleled level of knowledge of biotech industry and dealmaking in the sector, in addition to their excellent support for their clients,” said Lyn Baranowski, Chief Operating Officer of Altavant Sciences. “We benefitted greatly from their expertise and look forward to working with them in the future.”
The transaction closed on December 30, 2019. Terms are not being disclosed.
The Hogan Lovells team was led by New York M&A partner Adam Golden, counsel Jessica Bisignano and associate Caroline Brown. Global Regulatory partner Susan Lee, Benefits counsel Michael Applebaum, Tax partner Christine Lane and senior associate Catherine Yiren Chen also advised on the matter.